Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688843 · ClinicalTrials.gov registry record · NA
Safety and Performance Study of the INGEVITY Lead
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 1,060
- Enrollment target
NCT01688843: Completed NA study, sponsored by Boston Scientific Corporation.
NCT01688843 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,060 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688843, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,060 participants
- Enrollment target
Study Summary
The objective of this study is to gather data to establish the safety, performance and effectiveness of the INGEVITY pace/ sense leads.
Primary Outcome
Lead-related complication-free rate from lead implant through the three month follow-up, based on complications that are related to the INGEVITY Lead. The performance goal based on similar leads was set in collaboration with FDA at 91.4%
Interventions
- DEVICE INGEVITY lead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,060 participants |
| Start Date | 2012-10 |
| Est. Completion | 2019-02 |
| Phase | NA |
What the finished NCT01688843 record still lists
NCT01688843 is an interventional study that assigns participants to a tested intervention. Its 1,060 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 1 intervention - of which INGEVITY lead is the first listed.
NCT01688843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01688843 about?
NCT01688843 is a clinical study titled "Safety and Performance Study of the INGEVITY Lead". The objective of this study is to gather data to establish the safety, performance and effectiveness of the INGEVITY pace/ sense leads.
What is the current status of trial NCT01688843?
This trial is currently completed. It is a NA study. The enrollment target is 1,060 participants. The study started on 2012-10. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01688843?
The interventions under investigation include: INGEVITY lead (DEVICE).
Who is sponsoring clinical trial NCT01688843?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01688843's enrollment target sits among peer trials
1,060 97th of 2000 higher than 1,903 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia